6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport

Sedation, Analgesia & Neuromuscular Blockade in Transport

Airway management and patient comfort during neonatal and pediatric critical care transport represent some of the highest-acuity interventions encountered in mobile intensive care. The physiological stress of transport—including vehicular vibration, gravitational acceleration forces, loud ambient noise, and thermal instability—exacerbates pain, agitation, and oxygen consumption. Transport clinicians must possess nuanced pharmacological mastery of induction agents, continuous sedatives, analgesics, and neuromuscular blockers, ensuring hemodynamic stability while avoiding catastrophic complications.

---

Transport Rapid Sequence Intubation (RSI) Protocols

Rapid Sequence Intubation in the transport environment differs markedly from controlled operating room induction. The patient often has severe physiological derangements (hypoxemia, hypovolemia, elevated intracranial pressure, or reactive airway disease), and the physical space inside an aircraft or ambulance severely restricts maneuverability.

The 7 Ps of Transport RSI

1. Preparation: Equipment verification (video laryngoscope, backup supraglottic airway, bougie, suction), medication calculation, and smart pump setup.
2. Preoxygenation: 3 minutes of high-flow 100% $\text{FiO}_2$ via non-rebreather or CPAP/BiPAP; avoid aggressive positive pressure ventilation if possible to minimize gastric insufflation.
3. Premedication: Administer vagolytic or sympathetic blunting agents 1–2 minutes prior to induction.
4. Paralysis with Induction: Immediate sequential administration of a potent sedative-hypnotic followed immediately by a rapid-acting neuromuscular blocker.
5. Positioning & Protection: Neutral airway alignment, ramped sniffing position for older children, shoulder roll for neonates, and passive oxygenation.
6. Placement with Proof: Visualized tube passage through the vocal cords, followed by mandatory continuous waveform capnography ($\text{EtCO}_2$) and bilateral auscultation.
7. Post-intubation Management: Secure tube at calculated depth, establish mechanical ventilation, and initiate continuous maintenance sedation.

---

Premedication Pharmacodynamics: Atropine & Glycopyrrolate

Neonates and young infants are predisposed to severe, life-threatening vagal bradycardia during airway manipulation. Parasympathetic tone predominates in early life, and direct stimulation of the laryngeal and pharyngeal mucosa by a laryngoscope blade triggers profound bradycardia. Furthermore, succinylcholine stimulates muscarinic receptors in the SA node, which can cause bradycardia or sinus arrest, especially with repeated doses.

• Atropine Sulfate (0.02 mg/kg IV/IO): Competitive muscarinic acetylcholine receptor antagonist. It blocks vagal afferents, increases SA nodal firing, and dries airway secretions.
  • Dose for Premedication: Since the 2015 update, AHA PALS guidance states that 0.02 mg/kg with no minimum dose may be considered when atropine is used as premedication for emergency intubation. The old 0.1 mg minimum came from concern about paradoxical bradycardia with tiny doses, but it can overdose small infants several-fold. The PALS bradycardia algorithm, a different indication, still lists a 0.1 mg minimum and a 0.5 mg maximum single dose.
  • When to Use It: Atropine is not required for every intubation. PALS considers it reasonable when bradycardia risk is higher, such as with succinylcholine (especially repeated doses) or in young infants with strong vagal responses. Many transport programs still premedicate infants by protocol.
• Glycopyrrolate (0.005–0.01 mg/kg, max 0.2 mg): A synthetic quaternary ammonium anticholinergic. Because it does not cross the blood-brain barrier, it produces potent antisialagogue (secretory drying) effects without causing central anticholinergic sedation or pupillary changes, preserving neurological assessment.

---

Induction Pharmacology: Matching the Agent to Patient Physiology

---

Neuromuscular Blocking Agents (NMBAs): Depolarizing vs. Non-Depolarizing

Neuromuscular blockers eliminate patient movement, prevent fighting the ventilator, ablate vocal cord motion during intubation, and eliminate shivering during therapeutic hypothermia.

Succinylcholine (1.5–2.0 mg/kg IV/IO, 3.0–4.0 mg/kg IM)

A depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor endplate, triggering persistent depolarization (fasciculations followed by flaccid paralysis).

• Pediatric Dosing Nuance: Infants and young children possess a larger extracellular fluid (ECF) volume distribution and require higher weight-based doses (2.0 mg/kg) compared to adolescents and adults (1.0–1.5 mg/kg).
• Rapid Onset & Short Duration: Onset in 30–60 seconds; duration of 5–10 minutes, making it the fastest agent for emergency airway control.
• Contraindications: (The FDA boxed warning concerns hyperkalemic cardiac arrest in children with undiagnosed myopathies.)
  1. Major thermal burns >24–48 hours old (extrajunctional acetylcholine receptor upregulation causes lethal potassium efflux).
  2. Extensive crush injury, denervating spinal cord trauma, or stroke >48 hours old.
  3. Pre-existing hyperkalemia (use extra caution in renal failure, where potassium may already be high).
  4. Known or suspected muscular dystrophies (e.g., Duchenne/Becker), where administration triggers rhabdomyolysis, catastrophic hyperkalemia, and cardiac arrest.
  5. Personal or family history of malignant hyperthermia.

Rocuronium (1.0–1.2 mg/kg IV/IO for RSI)

A monoquaternary aminosteroid non-depolarizing NMBA that competitively antagonizes nicotinic acetylcholine receptors without triggering depolarization.

• RSI Dosing: While 0.6 mg/kg produces paralysis in 90–120 seconds, the standard transport RSI dose is 1.0 to 1.2 mg/kg, which shortens onset time to 45–60 seconds (comparable to succinylcholine).
• Duration: 45 to 90 minutes. Because rocuronium has a prolonged duration, the transport crew must be fully prepared to manage a failed airway throughout the entire flight.
• Reversal: Directly encapsulated and neutralized by sugammadex.

Vecuronium (0.1 mg/kg IV/IO)

Non-depolarizing aminosteroid with an onset of 2–3 minutes and duration of 30–45 minutes. Primarily utilized for post-intubation maintenance paralysis rather than rapid induction.

---

Acute Complication: Fentanyl-Induced Rigid Chest Syndrome

A critical, life-threatening adverse event frequently tested on the C-NPT exam is wooden chest syndrome (fentanyl-induced chest wall rigidity). This phenomenon occurs when fentanyl is administered as a rapid intravenous push, particularly at high doses (>3–5 mcg/kg) or in neonates and young infants.

• Pathophysiology: Centrally mediated stimulation of striatal GABA and mu-opioid pathways produces intense hypertonus of the intercostal, diaphragm, abdominal, and laryngeal muscles.
• Clinical Presentation: Within seconds of injection, the patient develops sudden, board-like chest wall rigidity, jaw clenching, and vocal cord adduction. The transport clinician becomes completely unable to ventilate the patient with a bag-valve-mask; peak inspiratory pressures spike to maximum, and the chest will not rise, followed by acute hypoxemic cyanosis and bradycardia.
• Immediate Management:
  1. Option A (Definitive Paralysis): Administer a rapid-acting neuromuscular blocker (rocuronium 1.0–1.2 mg/kg or succinylcholine if not contraindicated). Paralysis immediately relaxes the skeletal and laryngeal musculature, permitting immediate bag-mask ventilation and tracheal intubation.
  2. Option B (Opioid Reversal): Administer Naloxone (0.01–0.1 mg/kg IV/IO). Naloxone displaces the opioid and resolves the rigidity within 1–2 minutes, but completely reverses analgesia and sedation.

---

Pain Assessment and Non-Pharmacologic Comfort

NCC lists pain management first under pharmacology. Pain in transport is often undertreated because children cannot report it and monitors mask it.

• Neonates: Validated tools include NIPS (Neonatal Infant Pain Scale), PIPP-R (Premature Infant Pain Profile–Revised), and N-PASS (Neonatal Pain, Agitation, and Sedation Scale), which also scores sedation in ventilated infants.
• Preverbal and nonverbal children: The FLACC scale (Face, Legs, Activity, Cry, Consolability).
• Children about 3–7 years and older: Faces scales such as Wong-Baker FACES or the Faces Pain Scale–Revised. Older children and adolescents can use a 0–10 numeric scale.
• Sedated or paralyzed patients: Watch for tachycardia, hypertension, tearing, and rising ICP. Paralysis removes behavioral signs, so analgesia must be scheduled rather than given only in response to visible distress.

Non-pharmacologic measures are part of treatment: swaddling and facilitated tucking, non-nutritive sucking with oral sucrose for brief neonatal procedures (per unit protocol), skin-to-skin contact or parental presence when possible, distraction for older children, and minimal handling and noise.

Analgesic options beyond opioids include acetaminophen (oral, rectal, or IV), ketamine (IV or intranasal), and local or topical anesthetics (for example, lidocaine for chest tubes and for IO insertion in conscious patients). NSAIDs are avoided with coagulopathy, kidney injury, and in some neonatal settings. Opioids remain the mainstay for severe pain and for ventilated patients.

Post-Intubation Maintenance Sedation & Pharmacological Reversal

Once an artificial airway is secured, the transport team must institute a continuous maintenance sedation protocol. Inadequate sedation leads to accidental extubation, ventilator dyssynchrony, elevated ICP, and intense psychological trauma, while over-sedation causes hemodynamic instability and prolonged recovery.

Continuous Maintenance Infusions

• Fentanyl: 1–4 mcg/kg/hr continuous IV infusion. Provides excellent analgesia with stable hemodynamics.
• Morphine: 10–40 mcg/kg/hr IV. Excellent for cardiac patients; produces modest venodilation that can lower preload beneficially in pulmonary edema, but risks histamine release and hypotension in hypovolemia.
• Dexmedetomidine (Precedex): 0.2–1.4 mcg/kg/hr IV. Selective alpha-2 agonist delivering 'cooperative' sedation without significant respiratory depression. Ideal for non-invasive ventilation or post-extubation transport; can cause bradycardia and biphasic blood pressure changes.
• Midazolam: 0.05–0.2 mg/kg/hr IV. Provides reliable amnesia and anxiolysis; should be titrated carefully with opioids to prevent synergistic vasodilation.

Pharmacological Reversal Protocols

• Naloxone (0.01–0.1 mg/kg IV/IO, max 2.0 mg): Pure mu-opioid competitive antagonist. In transport, titrate in small increments (0.005–0.01 mg/kg) when reversing unintended respiratory depression to preserve analgesia, unless patient is in full respiratory arrest.
• Flumazenil (0.01 mg/kg, max 0.2 mg): Specific benzodiazepine antagonist. Caution: Contraindicated in patients with known seizure disorders, chronic benzodiazepine therapy, or tricyclic antidepressant ingestion due to the risk of intractable status epilepticus.
• Sugammadex: Modified gamma-cyclodextrin that selectively encapsulates rocuronium and vecuronium in plasma. Dose: 2 mg/kg for routine reversal (reappearance of $T_2$ on train-of-four); 4 mg/kg for deep neuromuscular block (1–2 post-tetanic twitches); 16 mg/kg for immediate emergency rescue reversal 3 minutes after a 1.2 mg/kg rocuronium RSI dose. In the U.S., pediatric labeling covers patients 2 years and older for the 2 and 4 mg/kg doses; the 16 mg/kg immediate-reversal dose comes from adult labeling.
• Neostigmine (0.05 mg/kg) + Glycopyrrolate (0.01 mg/kg): Traditional reversal for non-depolarizing blockers; acetylcholinesterase inhibition combined with an anticholinergic to prevent muscarinic bradycardia.